Demonstrates the impact of AID expression on overall survival in diffuse large B-cell lymphoma patients treated with rituximab, suggesting implications for treatment.
BACKGROUND: A number of studies have demonstrated the important role of activation-induced cytidine deaminase (AID) in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). AID has been relatively underexplored as a prognostic factor in DLBCL, and its role remains controversial. AIMS: This study conducted a comprehensive analysis of the association between AID expression and clinical outcomes in 70 Indonesian patients with DLBCL treated with a standard CHOP ± rituximab regimen. METHODS AND RESULTS: Immunostaining results showed that AID was expressed in 35.7% of DLBCL samples. Multivariate analysis indicated that positive AID expression was associated with shorter overall survival (OS) specifically among patients receiving a rituximab-containing regimen, with a hazard ratio of 10.39 (95% CI: 1.93-55.96; p = 0.006). CONCLUSION: The significant prognostic value of AID in the DLBCL subgroup treated with rituximab-but not in the general DLBCL population or in those not receiving rituximab-underscores the potential relevance of AID expression in DLBCL management and treatment decisions.
No takes yet. Share an insight, caveat, or question.
Hardianti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: